对合成生物学项目的双重使用风险评估的映射变化
Daniel Greene1, Tessa Alexanian2, Megan J Palmer1,3
1Center for International Security and Cooperation, Stanford University, Stanford, CA, United States.
Frontiers in bioengineering and biotechnology
|September 2, 2025
概括
评估涉及双重用途的研究 (DURC) 显示了审查员在风险和管理策略上的重大分歧. 这种不一致表明需要改进DURC风险评估方法以确保公共安全.
科学领域:
- 生物科学
- 生物安全
- 合成生物学
背景情况:
- 美国政府政策建议对潜在的双重用途研究进行风险评估 (DURC).
- 生物风险管理专业人士建议使用风险评估结果来选择适当的风险管理策略.
- 对现实世界DURC评估,审核员协议和战略绘制的实证研究是有限的.
研究的目的:
- 调查DURC风险评估的一致性和准确性.
- 分析对现实项目风险和管理策略的审查者协议.
- 开发更一致,更准确,更具成本效益的DURC风险评估方法.
主要方法:
- 使用了美国政府对生命科学双重使用研究的监督政策的修改框架.
- 18名经验丰富的DURC审查员和49名合成生物学学生提供了详细的评论.
- 对四个现实世界合成生物学项目的风险,益处和建议的风险管理策略进行了审查.
主要成果:
- 在专家和学生之间观察到的DURC风险和推的管理策略存在显著差异.
- 专家对一些项目的风险评估包括5种可能的评级中的4种.
- 关于管理DURC风险的适当行动存在重大分歧.
结论:
- 观察到的判断差异表明DURC风险管理的机构标准不一致.
- 不一致的标准可能会使公众面临不同程度的风险.
- 提供基于研究的建议,以减少审查员的分歧和提高风险管理效率.
相关概念视频
Mutagenicity and Carcinogenicity
1.4K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.4K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
174
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
174
Mismatch Repair
5.2K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
5.2K


